Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

322 ARTÍCULOS , VIENDO DEL 181 AL 195

B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia: a systematic review

Dangour AD, Whitehouse PJ, Rafferty K, Mitchell SA, Smith L, Hawkesworth S, Vellas B.

J Alzheimers Dis. 2010;22(1):205-24. doi: 10.3233/JAD-2010-090940.

Effect of an antioxidant drink on homocysteine levels in Alzheimer's patients

Morillas-Ruiz JM, Rubio-Perez JM, Albaladejo MD, Zafrilla P, Parra S, Vidal-Guevara ML.

J Neurol Sci. 2010 Dec 15;299(1-2):175-8. doi: 10.1016/j.jns.2010.08.050. Epub 2010 Sep 20.

[Therapeutic strategies for Alzheimer disease based on endoplasmic reticulum stress]

Kudo T.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Aug;30(4):163-8.

[Immunotherapy and Alzheimer's disease]

Arai H.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Aug;30(4):173-6.

Development of the Japanese DOLOPLUS-2: a pain assessment scale for the elderly with Alzheimer's disease

Ando C, Hishinuma M.

Psychogeriatrics. 2010 Sep;10(3):131-7. doi: 10.1111/j.1479-8301.2010.00324.x. Epub 2010 Aug 28.

Evidence supporting technology-based interventions for people with early-stage Alzheimer's disease

Buettner LL, Yu F, Burgener SC.

J Gerontol Nurs. 2010 Oct;36(10):15-9. doi: 10.3928/00989134-20100831-01. Epub 2010 Sep 22.

Finding the right target for treating Alzheimer disease

Mandell BF.

Cleve Clin J Med. 2010 Oct;77(10):650. doi: 10.3949/ccjm.77b.10010.

Health economics and health policy issues in Alzheimer's disease

Rapp T.

J Nutr Health Aging. 2010 Oct;14(8):630-2. doi: 10.1007/s12603-010-0308-2.

Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments

McNamee P, Vanoli A, Hutchings D, McKeith I, Bond J.

J Nutr Health Aging. 2010 Oct;14(8):664-8. doi: 10.1007/s12603-010-0313-5.

Phenserine efficacy in Alzheimer's disease

Winblad B, Giacobini E, Frölich L, Friedhoff LT, Bruinsma G, Becker RE, Greig NH.

J Alzheimers Dis. 2010;22(4):1201-8. doi: 10.3233/JAD-2010-101311.

The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease

Cappell J, Herrmann N, Cornish S, Lanctôt KL.

CNS Drugs. 2010 Nov;24(11):909-27. doi: 10.2165/11539530-000000000-00000.

Investigational medications for treatment of patients with Alzheimer disease

Potter PE.

J Am Osteopath Assoc. 2010 Sep;110(9 Suppl 8):S27-36.

Recruitment of subjects into clinical trials for Alzheimer disease

Knebl JA, Patki D.

J Am Osteopath Assoc. 2010 Sep;110(9 Suppl 8):S43-9.

Phosphodiesterase-5 inhibitors: novel weapons against Alzheimer's disease?

Sabayan B, Zamiri N, Farshchizarabi S, Sabayan B.

Int J Neurosci. 2010 Dec;120(12):746-51. doi: 10.3109/00207454.2010.520381. Epub 2010 Oct 13.

Novel drug targets based on metallobiology of Alzheimer's disease

Bandyopadhyay S, Huang X, Lahiri DK, Rogers JT.

Expert Opin Ther Targets. 2010 Nov;14(11):1177-97. doi: 10.1517/14728222.2010.525352.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias